Vividion Therapeutics

Market position

Vividion is one of several companies pursuing chemoproteomics-based drug discovery; C&EN notes Novartis and UC Berkeley established a virtual chemoproteomics research center in 2017 and cites Berkeley-derived startup Frontier Medicines as another entrant. Third-party data list peer companies including Relay Therapeutics, Kymera Therapeutics, Nimbus Therapeutics, Morphic Therapeutic, Pionyr Immunotherapeutics and Cyteir Therapeutics. Its acquisition by Bayer for up to $2 billion before it had any clinical-stage candidates indicates the perceived value of its platform.

Vividion contrasts its covalent-first method with traditional small molecule discovery, which it says is limited to proteins with deep pockets that bind small-molecule metabolites and often yields potent but non-selective, non-permanent binding. By using covalent fragments that exploit shallow pockets and require only a small contact surface, the company argues it can address targets such as transcription factors and ubiquitin ligases. It cites continuous, iterative expansion of its covalent library, proteome-wide selectivity assessment in parallel with potency measurement, and its integrated data portal as sources of durable competitive advantage. Its RAS-PIK3CA program is described as blocking the RAS-PIK3CA interaction rather than the protein's active site, aiming to avoid tolerability problems associated with existing molecules.

Technology

The platform rests on three components: a custom library of over 50,000 covalent small-molecule fragments designed to be unreactive until they encounter a complementary protein surface, with a focus on reactive cysteines; an industrialized screening operation using high-resolution, high-throughput mass spectrometry to probe thousands of proteins in parallel in their native cellular state, providing real-time proteome-wide selectivity assessment; and an integrated data portal that overlays roughly 250,000 new data points per day with public human genetics and structural biology datasets. The approach is used to identify allosteric or cryptic binding pockets, uncover new mechanisms of action, and enable inhibition, activation, protein-protein interaction disruption and induced-proximity/targeted protein degradation strategies.

Go-to-market

As a Bayer subsidiary, Vividion advances internally discovered candidates through its own clinical trials while engaging in collaborations and licensing arrangements; prior partnerships with Roche and Bristol Myers Squibb (via Celgene) covered specific target programs, and it has collaborated with academic groups such as the Francis Crick Institute on RAS-PI3K biology. It has also expanded capabilities through acquisition, buying Tavros Therapeutics in January 2025 and acquiring exclusive global rights to VVD-214 in June 2025.

Patients with cancers, particularly solid tumors including NRF2-activated cancers (non-small cell lung, esophageal squamous cell and head and neck squamous cell carcinoma), microsatellite instability-positive colorectal, endometrial and gastric cancers, and RAS-driven cancers, as well as patients with immunological diseases. Commercially, the company's counterparties are large pharmaceutical partners and its parent Bayer.

Geography

Vividion's corporate headquarters and R&D center are in San Diego, California; the July 2024 expansion announcement described a new San Diego facility as its global R&D center and corporate headquarters. A data aggregator reports employees across three continents (North America, Europe and Asia). Its parent, Bayer AG, is a global enterprise with U.S. life science sites including Boston, San Francisco and Research Triangle Park.

History

The company was founded by Scripps Research chemists Benjamin F. Cravatt, Phil S. Baran and Jin-Quan Yu, with C&EN describing its formation in 2014. Before its acquisition it raised roughly $500 million, including investments from Roche and Celgene (later acquired by Bristol Myers Squibb), and had established discovery collaborations with both partners covering STAT3 inhibitors (BMS) and Werner syndrome helicase inhibitors and protein degraders (Roche). In August 2021 Bayer acquired the company for $1.5 billion upfront plus up to $500 million in milestones, with Vividion continuing to operate autonomously. Since then the company appointed Aleksandra Rizo as President and Head of R&D (2022) and CEO (2023), promoted Matt Patricelli to Chief Scientific Officer (2023) and Jean Bemis to Chief Operating Officer (announced January 2025), announced a new San Diego R&D center and corporate headquarters (July 2024), acquired precision oncology company Tavros Therapeutics (January 2025), obtained global rights to VVD-214 (June 2025), and hired Sam Whiting as Chief Medical Officer (August 2025).

Risks & controversies

No controversies are described in the sources. Notable risk factors implicit in the material include a pipeline whose most advanced programs are still in Phase 1/1b, dependence on a single corporate parent for funding and strategic direction, and reliance on an unproven platform approach to targets that have resisted conventional drug discovery. Third-party aggregator figures for funding, revenue and headcount differ from primary sources and should be treated as unverified.